Pharmaceutical Technology
Zydus Lifesciences is set to acquire all outstanding Assertio common shares in a $166.4m deal, via its subsidiary Zydus Worldwide DMCC.
Pharmaceutical Technology
Zydus Lifesciences is set to acquire all outstanding Assertio common shares in a $166.4m deal, via its subsidiary Zydus Worldwide DMCC.
Pharmaceutical Technology
Zydus Lifesciences is set to acquire all outstanding Assertio common shares in a $166.4m deal, via its subsidiary Zydus Worldwide DMCC.